Adam Brufsky, MD, PhD

This segment explores the growing role of genomic testing and multidisciplinary coordination in the management of hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores deeper clinical interpretations of the SERENA-6 trial, particularly focusing on circulating tumor DNA dynamics and their relevance in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky introduces the trial within the context of ongoing regulatory and clinical debate regarding biomarker-driven intervention prior to radiographic progression.

This segment examines real-world access and reimbursement considerations influencing the use of oral selective estrogen receptor degraders in hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.

This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.

Delays in breast cancer diagnosis and treatment highlight the need for improved human capital investment in health care systems, explains Adam Brufsky, MD, PhD.

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.

Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.